<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:bovine-ojs-tamu.tdl.org:article/8004</identifier>
				<datestamp>2021-08-31T18:52:21Z</datestamp>
				<setSpec>bovine:ART</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Clinical effectiveness of enrofloxacin 100 mg/mL injectable solution for the treatment of acute anaplasmosis in cattle caused by Anaplasma marginale</dc:title>
	<dc:creator xml:lang="en">Shane, Douglas D.</dc:creator>
	<dc:creator xml:lang="en">Lechtenberg, Kelly F.</dc:creator>
	<dc:creator xml:lang="en">Seagren, Jon</dc:creator>
	<dc:creator xml:lang="en">Tessman, Ronald K.</dc:creator>
	<dc:creator xml:lang="en">Singu, Vijaya Krishna</dc:creator>
	<dc:creator xml:lang="en">Wang, Yingying</dc:creator>
	<dc:creator xml:lang="en">Coetzee, Johann</dc:creator>
	<dc:creator xml:lang="en">Reif, Kathryn E.</dc:creator>
	<dc:subject xml:lang="en">Anaplasma marginale</dc:subject>
	<dc:subject xml:lang="en">anaplasmosis</dc:subject>
	<dc:subject xml:lang="en">treatment</dc:subject>
	<dc:subject xml:lang="en">enrofloxacin</dc:subject>
	<dc:subject xml:lang="en">bovine</dc:subject>
	<dc:description xml:lang="en">Anaplasma marginale is a gram-negative rickettsial pathogen that can cause clinical anemia and death in cattle. The objective of this study was to evaluate the effectiveness of enrofloxacin (ENR) 100 mg/mL at a single subcutaneous dose of 5.7 mg/lb (12.5 mg/kg) for treatment of acute anaplasmosis (ANA) in mature beef cows (n=67). Following intravenous inoculation with A. marginale-infected blood, cattle were monitored for clinical signs of ANA. Upon meeting case criteria, cattle were randomly assigned to receive ENR or saline (SAL). Treatment success, defined as 28 d post-treatment survival and resolution of abnormal clinical scores, was 81.8% (27/33) and 44.1% (15/34) (P=0.0032) for ENR and SAL treated cows, respectively. Mortality was 47% (16/34) and 3% (1/33) in SAL and ENR, respectively (P=0.0027). Packed cell volume at 7, 14, 21, and 28 d post-treatment was significantly greater in ENR compared to SAL (P&amp;lt;0.05). In this study, ENR improved treatment success compared to SAL, reduced ANA mortality, and maintained greater packed cell volumes post-clinical signs compared to SAL. Extra-label use of fluoroquinolones in food animals is prohibited in the United States, but ENR (BaytrilÂ® 100-CA1) was recently conditionally approved for treatment of ANA.</dc:description>
	<dc:publisher xml:lang="en">American Association of Bovine Practitioners</dc:publisher>
	<dc:date>2020-02-01</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://bovine-ojs-tamu.tdl.org/bovine/article/view/8004</dc:identifier>
	<dc:identifier>10.21423/bovine-vol54no1p51-57</dc:identifier>
	<dc:source xml:lang="en">The Bovine Practitioner; Vol. 54, No. 1 (2020 Spring); 51-57</dc:source>
	<dc:source>0524-1685</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://bovine-ojs-tamu.tdl.org/bovine/article/view/8004/7589</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2020 The Bovine Practitioner</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
